Generation Bio Co Ordinary Shares GBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GBIO is a good fit for your portfolio.
News
-
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Thinking about buying stock in CureVac, Quantum-Si, Clearone, Rambus, or Generation Bio?
-
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
-
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
-
Coinbase's stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move
-
Generation Bio, Moderna announce collaboration
-
Generation Bio, Moderna Enter Collaboration to Accelerate Non-Viral Genetic-Medicines Pipeline
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.75–3.08
- 52-Week Range
- $0.86–6.98
- Bid/Ask
- $2.47 / $2.81
- Market Cap
- $184.81 Mil
- Volume/Avg
- 199,241 / 247,253
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 174
- Website
- https://www.generationbio.com
Comparables
Valuation
|
Metric
|
GBIO
|
CBAY
|
DSGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.91 | 12.65 | 0.75 |
Price/Sales | 30.36 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
GBIO
CBAY
DSGN
Financial Strength
|
Metric
|
GBIO
|
CBAY
|
DSGN
|
|---|---|---|---|
Quick Ratio | 6.73 | 10.70 | 29.44 |
Current Ratio | 6.83 | 10.96 | 29.58 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
GBIO
CBAY
DSGN
Profitability
|
Metric
|
GBIO
|
CBAY
|
DSGN
|
|---|---|---|---|
Return on Assets (Normalized) | −25.96% | −30.06% | −17.16% |
Return on Equity (Normalized) | −40.85% | −51.97% | −17.93% |
Return on Invested Capital (Normalized) | −34.11% | −30.87% | −17.73% |
Return on Assets
GBIO
CBAY
DSGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pypshmczh | Kqftc | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gppgtbhd | Fpccw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hqkndxm | Pftzsv | $98.1 Bil | |
MRNA
| Moderna Inc | Jbbcphp | Jylpt | $39.7 Bil | |
ARGX
| argenx SE ADR | Htnjwtpp | Zxtp | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Jjnrjfrj | Bdks | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fjbqsdrd | Dppxf | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Krxxkdvq | Lrrfb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xnflqrng | Trvgpdt | $12.5 Bil | |
INCY
| Incyte Corp | Gbvszxstq | Mxbxfx | $11.8 Bil |